elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
Pricing
Log in
Sign up
Home
/
Subjects
/
Avelumab
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Avelumab
RIS
0.002
(Research Intensity Score)
Papers
95
Top papers
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
2020 · 1524 citations
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
2021 · 637 citations
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
2021 · 415 citations
The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
2021 · 297 citations
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
2018 · 397 citations
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
2017 · 588 citations
Role of immunotherapy in bladder cancer
2020 · 109 citations
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): “Real World” Experience
2023 · 30 citations
Diagnosis and Management of Upper Tract Urothelial Carcinoma: A Review
2025 · 13 citations
Newest papers
IZABRIGHT-Bladder01: A randomized, open-label, phase 2/3 trial of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), vs platinum-based chemotherapy (PBC) for patients (pts) with advanced urothelial cancer (aUC) and disease progression on or after immunotherapy.
2026 · 1 citations
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
2026 · 1 citations
Platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma: a real-world study
2026
Systemic therapy for urothelial cancer: platinum defeated?
2026
Diagnosis and Management of Upper Tract Urothelial Carcinoma: A Review
2025 · 13 citations
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab
2025 · 13 citations
Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Landscape and Future Directions
2025 · 12 citations
Three versus six cycles of platinum-based chemotherapy followed by avelumab maintenance as first-line treatment for advanced urothelial cancer: the phase II DISCUS trial
2025 · 9 citations
Influence of best objective response to first‐line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin
2025 · 10 citations
Browse all papers →
Avelumab's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Avelumab's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link